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Prolyl hydroxylase domain 3 (PHD3) is a hypoxia inducible factor-α (HIFα) regulator; it degrades HIFα in the
presence of oxygen. Recently, there have been an increasing number of studies about the role of PHD3 in
proliferation and apoptosis of cancer cells. However, most of the evidence for the role of PHD3 is observational,
and little is known of the molecular mechanism. In our current study, we constructed a recombinant eukaryotic
expression vector containing the PHD3 gene and detected its biological activity in human hepatoma cell line
(HepG2 cells). We successfully constructed a recombinant pcDNA 3.1(+)-PHD3 plasmid; the results showed that
PHD3 overexpression could inhibit the proliferation of HepG2 cells and induce apoptosis by activating caspase-3
activity. Our study has provided preliminary materials and data for further investigation of the effect of PHD3 on
HepG2 cells.
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There are three prolyl hydroxylase domain proteins
(PHDs), PHD1, PHD2 and PHD3, that are the key re-
gulators of degradation of hypoxia inducible factor (HIF)
in mammals. They are known as HIF-prolyl hydroxylase
(HPHs) in Drosophila and egg-laying nine (EGLN or
EGL-9) in C. elegans [1,2]. PHD1 and PHD2 mRNAs are
highly expressed in placenta, and PHD3 mRNA is highly
expressed in both placenta and heart [3]. In the presence
of oxygen, two of the proline residues of HIFα are hydro-
xylated by PHDs, which allows specific recognition and
binding of von Hippel-Lindau tumor suppressor protein
(pVHL) and then leads to the subsequent ubiquitination
and proteosomal degradation of HIFα [4]. In addition,
PHDs play a novel role in tumor progression and develop-
ment [5], especially PHD3. Recently, an increasing num-
ber of studies have indicated that PHD3 is involved in
the development and prognosis of cancer [6-10] and also* Correspondence: lianqilian@gdmc.edu.cn
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reproduction in any medium, provided the orappears to induce apoptosis in cancer cells [11-13]. How-
ever, most of these studies are observational, and know-
ledge of PHD3’s molecular mechanism is still limited. In
our current study, we constructed a eukaryotic expression
vector containing the PHD3 gene and detected its expres-
sion in human hepatoma cell line (HepG2) cells to estab-
lish a foundation for future studies.Materials and methods
Materials
Plasmid pcDNA 3.1(+) was obtained from the Central
Laboratory of Affiliated Hospital of Guangdong Medical
College (Guangdong, China). E. coli DH5α was gained
from the Pathogenic Biology Laboratory of Guangdong
Medical College. Human hepatoma cells (HepG2) were
obtained from the Laboratory of Hepatobiliary Surgery.
Placenta tissue and the written informed consent for
this tissue were obtained from the Operating Room
of Affiliated Hospital of Guangdong Medical College.
RNAiso Plus, High Fidelity Prime Script™ RT-PCR Kit,
TaKaRa Agarose Gel DNA Purification Kit Ver.2.0,
DL10,000 DNA Marker, DNA A-Tailing Kit, pMD19-T
Simple Vector, DNA Ligation Kit Ver.2.0, Hind III, Xho I,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic representation of constructed recombinant pcDNA 3.1(+)-PHD3 eukaryotic expression vector.
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SYBR® Prime Script® RT-PCR Kit II (Perfect Real Time)
were purchased from TAKARA (Japan). Neonatal Bovine
Serum was acquired from Hangzhou Sijiqing Biological
Engineering Materials Co., Ltd (China). Dulbecco's modi-
fied Eagle’s medium(DMEM)was purchased from Hyclone
Company (USA). Lipofectamine™ 2000 was purchased
from Invitrogen Biotechnology (USA). DMSO was pur-
chased from Sigma (USA). 3-(4,5-Dimethyl-2-Thiazolyl)-
2,5-Diphenyl Tetrazolium Bromide (MTT) was purchased
from Sangon Biotech (Shanghai) Co., Ltd (China). Pri-
mary rabbit polyclonal anti-EGLN3 antibody was pur-
chased from Jiamay Biotech Company (China). Primary
rabbit polyclonal anti-Caspase-3 antibody was purchased
from Zhongshan Goldenbridge Biotechnology CO., LTD
(China). Primary rabbit polyclonal anti-tubulin antibody, a
BCA protein assay kit and BeyoECL Plus were purchased
from Beyotime Institute of Biotechnology (China).
Vector construction
Total RNA extraction and PHD3 cDNA synthesis
Total RNA from placental tissue was extracted with
RNAiso Plus according to the manufacturer’s instructions.
First, 1 μg of total RNA was used to synthesize full-length
PHD3 CDS with High Fidelity Prime Script™ RT-PCR Kit.
A pair of specific primers, containing Hind III and Xho I
restriction enzyme cutting sites, were designed: forward
50-CCCAAGCTTGATGCCCCTGGGACACATCAT-30
and reverse 50-CCGCTCGAGTCAGTCTTCAGTGAGGG-
CAGA-30.
Purification of PHD3 cDNA and ligation with pMD19-T
simple vector
The RT-PCR products were separated with 1.5% agarose
gel electrophoresis, and the target fragments were re-
trieved and purified by TaKaRa Agarose Gel DNA Purifi-
cation Kit v.2.0. The target fragments were polyadenylated
using DNA A-Tailing Kit; these fragments were thenFigure 2 Identification of PHD3. (A) Electrophoresis of full-length target
(B) Hind III and Xho I digestion and electrophoresis of pcDNA 3.1(+)-PHD3
2: pcDNA 3.1(+) plasmid digested by Hind III and Xho I, 3: pcDNA 3.1(+)-PHligated into pMD19-T Simple Vector with DNA Ligation
Kit v.2.0 (TA Clone). The recombinant pMD19-T-PHD3
was transformed into E. coli DH5α competent cells for
amplification. Recombinant vectors were isolated from
transformants by TaKaRa MiniBEST Plasmid Purification
Kit v.2.0, and the pMD19-T-PHD3 was sequenced by an
ABI 377 DNA sequencer (Applied Biosystems, USA).
Construction of recombinant pcDNA 3.1(+)-PHD3 eukaryotic
expression vector
The pMD19-T-PHD3 plasmids were digested by Hind
III and Xho I restriction enzymes, and the target frag-
ments (full length PHD3 cDNAs) were isolated and pu-
rified. The pcDNA 3.1(+) eukaryotic expression vectors
were also digested by Hind III and Xho I and then li-
gated into PHD3 cDNA with DNA Ligation Kit v.2.0.
The recombinant pcDNA 3.1(+)-PHD3 was amplified in
E. coli DH5α competent cells, and isolated with TaKaRa
MiniBEST Plasmid Purification Kit v.2.0. The correct
pcDNA 3.1(+)-PHD3 plasmid sequence was verified by
restriction enzyme mapping and DNA sequencing.
A Schematic representation of the construction of the
recombinant pcDNA 3.1(+)-PHD3 eukaryotic expression
vector is presented in Figure 1.
Expression of the recombinant pcDNA 3.1(+)-PHD3
eukaryotic expression vector in HepG2 cells
Cell transfection
HepG2 cells were cultured in DMEM containing 10%
Neonatal Bovine Serum at 37°C in a humidified atmos-
phere of 5% CO2. Cells were passaged and plated (12-well
plates for mRNA assay, 6-well plates for western blot and
96-well plates for growth curve assay) for 24 hours before
transfection at 80% –90% confluence. Cells were divided
into four groups: no treatment (Normal), Lipofectamine™
2000 (LP2000), Lipofectamine™ 2000 + pcDNA 3.1(+)
(PC3.1) and Lipofectamine™ 2000 + pcDNA 3.1(+)-PHD3
(PHD3). Transfection was carried out according togene RT-PCR product; M: DNA Marker DL10,000, 1: PHD3.
eukaryotic expression vector; M: DNA Marker DL10,000, 1: PHD3,
D3 plasmid digested by Hind III and Xho I.
Figure 3 Sequence of full-length 721 bp PHD3 gene.
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transfection, cells were collected to conduct subsequent
assays.
Detection of PHD3 mRNA by quantitative real time RT-PCR
Total RNA was isolated from transfected cells by
RNAiso Plus, and 500 ng of total RNA was analyzedFigure 4 Expression and biological activity of PHD3. (A) PHD3 mRNA
with PHD3 significantly overexpressed PHD3, compared with the control g
blot. Cells transfected with PHD3 significantly overexpressed PHD3, compa
Lipofectamine™ 2000, PC3.1: Lipofectamine™ 2000+pcDNA 3.1(+), PHD3: Lip
significant differences in comparison to PHD3-transfected cells.with SYBR® Prime Script® RT-PCR Kit II on a LightCy-
cler480 (Roche, Switzerland) according to manufacturer’s
instructions. The primers were as follows: PHD3 forward
5’- CATCAGCTTCCTCCTGTC-3’, reverse 5’- CCACCA
TTGCCTTAGACC-3’ and β-actin forward 5’- CTGTGC
CCATCTACGAGG-3’, reverse 5’- ATGTCACGCACGAT
TTCC-3’. The data were analyzed using Ct method.was measured by quantitative real-time RT-PCR. Cells transfected
roups (all P=0.00). (B and C) PHD3 protein was analyzed by western
red with the control groups (all P=0.00). Normal: no treatment, LP2000:
ofectamine™ 2000+pcDNA 3.1(+)-PHD3. #P<0.05 indicates statistically
Figure 5 HepG2 cell growth curves. Compared with the control
groups, PHD overexpression significantly inhibited cell
proliferation (all P=0.00). Normal: no treatment, LP2000:
Lipofectamine™ 2000, PC3.1: Lipofectamine™ 2000+pcDNA 3.1(+),
PHD3: Lipofectamine™ 2000+pcDNA 3.1(+)-PHD3.
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After transfection, cells were collected and lysed, and
the protein concentration was detected by BCA protein
assay kit. Supernatants were loaded on a 12%SDS–PAGE
gel, and they were then wet transferred onto PVDF
membranes. The membranes were incubated with their
respective primary antibodies, followed by incubation
with HRP-conjugate secondary antibodies. The bands
were visualized with BeyoECL Plus and exposed to X-ray
film.Figure 6 Activation of caspase-3. Cells transfected with the cleaved 1
than the control groups (all P=0.00). Normal: no treatment, LP2000: Lipo
Lipofectamine™ 2000+pcDNA 3.1(+)-PHD3. #P<0.05 indicates statistically sigCell proliferation assay
To analyze the effects of PHD3 on proliferation of
HepG2 cells, MTT assay was performed. Cells were cul-
tured in 96-well plates, and a total cell number was
detected every 12 hours. At each time point, twenty μl
of MTT (5 mg/ml) was added to each well, and incubated
at 37°C for 4 hours. The supernatant was discarded, and
150 μl of DMSO was added to each well. The absorbance
(OD value) of the cells was measured using a micro plate
reader (Thermo, USA) with a 492 nm filter.Statistical analysis
The data were presented as mean ± SD based on three in-
dependent experiments. Statistical comparisons between
two groups were made by Student’s t test, and the cell
growth curve was analyzed with multivariate analysis of
variance (MANOVA). Statistical analyses were performed
by using SPSS 13.0 software for windows (SPSS Inc., USA).
Statistical significance was defined as P < 0.05.Results
Evaluation of RT-PCR product and recombinant pcDNA
3.1(+)-PHD3 eukaryotic expression vector
The RT-PCR products were loaded on 1.5% agarose gels,
and the band for full-length PHD3 cDNA was located at
721 bp (Figure 2A). After the PHD3 cDNA fragment was
inserted into the pcDNA 3.1(+) plasmid (5428 bp), the
fragment was confirmed by Hind III and Xho I digestion
and electrophoresis (Figure 2B). Additionally, the cDNA
was confirmed by DNA sequencing, as shown in Figure 3.
mRNA and protein expressions of PHD3 in HepG2 cells
After transfection, the expression of PHD3 was analyzed
by quantitative real-time RT-PCR and western blot.
The results showed that the PHD3 transfected group7 kD active caspase-3 fragment of PHD3 expressed more protein
fectamine™ 2000, PC3.1: Lipofectamine™ 2000+pcDNA 3.1(+), PHD3:
nificant differences in comparison to PHD3-transfected cells.
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red with the control groups (Figure 4A, Figure 4B and
Figure 4C).
Effect of PHD3 on proliferation of HepG2 cells
The OD value of each group was obtained by measuring
it every 12 h after transfection, for up to 72 h. Cell pro-
liferation curves were depicted with mean OD values of
each time point. As shown in Figure 5, the pcDNA 3.1
(+)-PHD3 transfected group grew slower than the con-
trol groups (all P = 0.00)
Effect of PHD3 on apoptosis of HepG2 cells
To investigate whether PHD3 has an effect on inducing
apoptosis in HepG2 cells, caspase-3 assays were per-
formed. We found that PHD3 overexpression increased
caspase-3 activity (all P = 0.00), and the cleaved 17 kD
active caspase-3 fragment was visualized by western blot
analysis (Figure 6A and Figure 6B).
Discussion
PHD3 was originally considered an HIFα regulator; it
played a vital role in the progression and prognosis of
cancer by targeting the degradation of HIFα. Recently, a
number of studies have shown that PHD3 was closely
related to cancer, independent of its hydroxylase activity.
Chen, S et al. [8] found that PHD3 was highly expressed
in lung cancer (NSCLC), associating with early-stage and
well differentiated tumors. Fox, S. B et al. [14] showed that
PHD3 expression was significantly increased after therapy
with epirubicin, alone or in combination with tamoxifen,
in patients with T2-4 N0-1 breast cancer; however, PHD3
expression was not relevant in treatment response and
survival. Su, C et al. [6] also demonstrated that the ex-
pression of PHD3 was significantly increased from non-
cancerous mucosa to cancer, and its high expression
correlated with well differentiated tumors. In contrast,
Couvelard, A et al. [10] discovered that high nuclear
PHD3 expression related to poor survival in patients with
pancreatic endocrine tumors. Gossage, L et al. [9] also
found that PHD3 expression in tumor tissue indicated a
worse overall disease-free survival in ampullary adenocar-
cinomas and pancreatic adenocarcinomas. These studies
suggested that the role of PHD3 varied from one cancer
type to another and that it could be a predictor for treat-
ment and prognosis of cancer. With an increased under-
standing of PHD3, more attention has been focused on its
ability to suppress tumor growth [11-13]; however, little is
known about PHD3’s exact mechanism. In pancreatic cells
overexpressing PHD3, Su, Y et al. [13] found that apop-
tosis increased sharply in the presence of nerve growth
factor by the activation of caspase-3. Tennant, D. A et al.
[12] demonstrated PHD3-mediated alpha-ketoglutarate-
induced apoptosis in three human colorectal cancer celllines (HCT116, A431 and A375). In colorectal cancer
cells, PHD3 inhibits cell growth by blocking IKKβ/NF-κ B
signaling [11].
So far, the relationship between PHD3 and hepatocel-
lular cancer (HCC) is still unclear. To clarify the effect
of PHD3 on HCC, we constructed a recombinant eukar-
yotic expression vector containing PHD3 and detected its
biological activities in HepG2 cells. The results showed
that pcDNA3.1(+)-PHD3 was successfully constructed,
and PHD3 could be overexpressed in HepG2 cells after
transient transfection. To investigate whether PHD3 can
inhibit HepG2 cells, we carried out a cell growth curve
assay and found that PHD3 arrested cell proliferation.
Moreover, we analyzed caspase-3 activity and clarified
whether PHD3 had an effect on apoptosis. We found that
the cleaved 17 kD active caspase-3 fragment was signifi-
cantly overexpressed in PHD3 group, which is in line with
previous studies [13,15].
In conclusion, we constructed a recombinant eukar-
yotic expression vector, pcDNA3.1(+)-PHD3, showing that
PHD3 overexpression can inhibit proliferation and induce
apoptosis in HepG2 cells. Our study has provided pre-
liminary data for further research of stably transfecting
pcDNA3.1(+)-PHD3 into HepG2 cell and clarifying the
mechanism of PHD3-induced apoptosis.
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